There is not enough capital to fund all of the good ideas from life science companies, which is a major challenge for life science CEOs today. To identify the next not-so-obvious investors, fundraising executives should look to the capital-raising practices of start-ups in other industries. If they do, they will learn that the basic premises include thinking outside the box and being flexible and more creative.
The economic turbulence of 2008 and 2011 has forced institutional investors and family offices to reevaluate how they fundamentally invest. The poor performance of some of VC and PE fund managers have concentrated fewer dollars in the hands of fewer managers, and the increased competition for those scarce dollars have slowed the life science market at a time when the number of potential technologies and products are surging. The banks, pensions, endowments, and insurance funds that made up a large portion of new VC and PE funds have become risk averse.
To read the full, original article click on this link: Family Offices: The New VCs – Life Science Nation
